Cardiac Allograft Vasculopathy Clinical Trials

38 clinical trials for Cardiac Allograft Vasculopathy across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• AERIAL Trial: Antiplatelet Therapy in Heart Transplantation — RECRUITING · PHASE3
• MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation — RECRUITING · NA
• Physiologic Assessment of Microvascular Function in Heart Transplant Patients — RECRUITING
• Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score — COMPLETED · PHASE3
• Early Post Transplant Cardiac Allograft Vasculopathy — ACTIVE_NOT_RECRUITING
• Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA — WITHDRAWN
• Comparing PCCT With ICA and IVUS in Detecting Cardiac Allograft Vasculopathy — NOT_YET_RECRUITING
• Unraveling Mechanism of Action of Extracorporeal Photopheresis in Heart and Lung Transplant Patients — COMPLETED
• Extracorporeal Photopheresis and Early Cardiac Graft Vasculopathy — COMPLETED · NA
• Microvascular Cardiac Allograft Vasculopathy Trial — OTHER
• Impact of SGLT2 Inhibitors in Heart Transplant Recipients — OTHER · PHASE2
• Endothelin-1 and Cardiac Allograft Vasculopathy (CAV) — COMPLETED · PHASE4
• Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients — COMPLETED · PHASE3
• Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients — OTHER · PHASE4
• Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft Vasculopathy — COMPLETED · PHASE4
• Potential Role of Donor-derived Cell-Free DNA as a Biomarker in Cardiac Allograft Vasculopathy — COMPLETED
• The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation — COMPLETED · PHASE3
• A P2X7R Single Nucleotide Mutation Promotes Chronic Allograft Vasculopathy — COMPLETED
• Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation — TERMINATED · PHASE2
• Cardiac Mitochondrial Function After Heart Transplantation — OTHER
• Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients — WITHDRAWN · NA
• HEart trAnsplantation Registry of piTie-Salpetriere University Hospital — COMPLETED
• Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy — COMPLETED · PHASE4
• A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV) — WITHDRAWN · PHASE3
• Effect of Ivabradine on Exercise Capacity After Heart Transplantation — OTHER · PHASE4
• Heart Failure After Heart Transplantation Due to Chronic Rejection — OTHER · NA
• EARLY POST TRANSPLANT CARDIAC ALLOGRAFT VASCULOPATHY (ECAV) — NOT_YET_RECRUITING
• Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation — TERMINATED · PHASE1
• Optical Coherence Tomography (OCT) to Evaluate Cardiac Allograft Vasculopathy (CAV) in Patient's Post Heart Transplant — COMPLETED
• Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy — COMPLETED · NA
• Noninvasive Predictors of Transplant Vasculopathy — WITHDRAWN
• Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients — WITHDRAWN · NA
• Noninvasive Evaluation of Cardiac Allograft Vasculopathy — WITHDRAWN
• Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation — COMPLETED · PHASE2
• Severe CAV MRI in Heart Transplant Recipient — WITHDRAWN
• Identification of Non Invasive Biomarkers of Immune Endothelial Injury and Repair Associated With Cardiac Allograft Vasculopathy — OTHER · NA
• Assessment of Cardiac Allograft Vasculopathy With Optical Coherence Tomography — COMPLETED
• Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy — OTHER · PHASE3

Refine this search